BioCity Group
VC Fund
Nottingham, United Kingdom
BioCity Group is a business incubator that aides in the creation and development of life science businesses.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries BioCity Group invests in
Stages BioCity Group invests in
Countries BioCity Group invests in
Investment Focus
Industry
- Biotechnology 4 (67%)
- Medical 2 (33%)
- Biopharma 2 (33%)
- Therapeutics 2 (33%)
- Health Care 1 (17%)
Stage
- Seed 2 (33%)
- Venture - Series Unknown 2 (33%)
- Series A 1 (17%)
- Funding Round 1 (17%)
Country
- United Kingdom 4 (67%)
- United States 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NanoSyrinx
|
NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy,safety, and economy. | $8.5M / Seed / Jul 19, 2021 | |
Rinri Therapeutics
|
Rinri Therapeutics is a provider of private biotechnology services intended to develop advanced regenerative stem cell-based therapies for the treatment of hearing loss. The company's stem cell technology replaces damaged or dead sensory cells of the inner ear, enabling doctors to restore hearing of patients. | $12M / Venture - Series Unknown / Apr 20, 2021 | |
Maxwellia
|
Maxwellia is a pioneering ‘prescription to over the counter’ medicines company which specialises in ‘switching’ - the conversion of prescription medicines into branded versions that can be bought without a prescription, over the counter (OTC). | $4.4M / Venture - Series Unknown / Apr 08, 2021 | |
Kinomica
|
Kinomica is a proteomic-data science and diagnostics company specializing in cell signalling. Kinomica offers KScanTM, a powerful suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can provide direct activity measurements of multiple endogenous kinases and comprehensive cell signalling network coverage. | $5.1M / Series A / Dec 14, 2020 | |
NuVision
|
NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at theUniversity of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham. | $1.8M / Sep 12, 2019 | |
|
Rinri Therapeutics
|
Rinri Therapeutics is a provider of private biotechnology services intended to develop advanced regenerative stem cell-based therapies for the treatment of hearing loss. The company's stem cell technology replaces damaged or dead sensory cells of the inner ear, enabling doctors to restore hearing of patients. | $1.8M / Seed / May 20, 2019 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does BioCity Group invest in?
BioCity Group invests primarily in Biotechnology, Medical and Biopharma startups, most often at Seed and Venture - Series Unknown stage. Most of the 6 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did BioCity Group last invest?
The most recent investment recorded for BioCity Group closed in Jul 2021. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
